Business Context and Reporting Period
This Form 8-K was filed by Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) on October 30, 2024, reporting events occurring on October 29 and October 30, 2024. The Company is incorporated in Delaware and its common stock (DWTX) trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory compliance and corporate announcements rather than financial performance data.
Material Changes
- Nasdaq Compliance: The Company regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. This was achieved after the common stock maintained a closing bid price of at least $1.00 per share for ten consecutive business days, closing the matter initiated by a Hearing Panel decision on June 11, 2024.
- Business Developments: On October 30, 2024, the Company issued a press release announcing key business developments (attached as Exhibit 99.1), though the specific details of these developments are not contained within the body of this 8-K text.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or a discussion of specific risks and contingencies beyond the resolution of the Nasdaq listing deficiency.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated October 30, 2024) to understand the specific "key business developments" mentioned.
- Verify the current stock price stability to ensure continued compliance with Nasdaq minimum bid price rules.
- Check subsequent filings (e.g., 10-Q or 10-K) for the actual financial metrics and cash position, as they are absent in this report.